| Autor: |
Svetlana V, Kalinichenko, Kristina V, Melentyevа, Hans, Manee, Natalia V, Dubinina, Natalia V, Zvereva, Inna I, Toryanik, Natalia G, Popova, Oleksandr V, Pakhomov |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Wiadomosci lekarskie (Warsaw, Poland : 1960). 73(7) |
| ISSN: |
0043-5147 |
| Popis: |
The aim: of the work was to study the antiviral activity of the metabolites of the probiotic strain Lactobacillus rhamnosus GG (LGG or ATCC 53103) regarding clinical strains of enteroviruses (Coxsackie B-5, ECNO21) isolated from the feces of intestinal infections.Materials and methods: The object of the study was substrate-dependent cell cultures of HeLa, Vero, Hep-2 lines. The titer of the virus was determined by the presence of a clear cytopathic action (CPA) in the monolayer infected cells of the virus.Results: Determination of the enteric virus infections activity in the culture fluid showed that in samples with the LGG metabolites, the infections activity of the clinical strains of enteroviruses decreased after 24 hours, at 1.5-1.7 (p0.05) times, and after 96 hours in 3, 6 - 5,7 times (p0,01). the processing of cell cultures by metabolites in the amount of 0.3 mg / ml contributed to a decrease in the titer of viruses by 2.77 ± 0.11 lg TCDD50 / cm3, 2.83 ± 0.11 lg TCD50 / cm3 and 2.94 ± 0.13 lg TCD50 / cm3 for Vero, HeLa and Hep-2 line cells in 24 hours.Conclusions: It has been experimentally determined that the maximum tolerated dose (MTD) of L. rhamnosus GG metabolites was 0.3 μg / ml for all cultures of cell lines. Determination of the antiviral activity of L. rhamnosus GG metabolites in clinical viruses of enteroviruses (Coxsackie B-5 and ECNO-21) showed a decrease in infection activity in 1.5-1.7 times, (p0.05) of clinical trials in clinical trials enteroviruses. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
